Trends of industry-leading biotechnology stocks during COVID-19


  • Navia Zhang Hong Kong International School
  • Meredith Haskins Mentor, Hong Kong International School



Biotechnology, Stocks, Trends, COVID-19


The 2019-nCoV coronavirus has significantly impacted the macroeconomic outlook for countries across the world. The biotechnology sector experienced a relatively positive stock price outlook, which corroborates the trends exhibited by biotechnology stocks in previous pandemics such as SARS (2003) and AH1N1 (2009). During the COVID-19 pandemic, vaccine roll-out rates have been more efficient than in any other pandemic, as companies today are more experienced in combating the time constraint to create vaccines. Gilead Sciences Inc. saw its shares rise 18% after developing the first FDA-approved COVID-19 vaccine, 'remdesivir'. In contrast, AstraZeneca's shares fell 2.28% in 2021 after its vaccine underwent investigations into blood-clotting side effects and subsequent suspension from several countries. Companies developing mRNA vaccines like Moderna, BioNTech, and Pfizer witnessed surges in share prices ranging from 10% to 20%. Many newer biotech companies such as Genexie, Sanovi, OnoSec, and Vaxart have also developed vaccines for COVID-19. Share prices are more volatile for these less established companies. This paper observes how developing new technologies, staging clinical trials, obtaining FDA approvals, gaining publicity, and several other complex factors have profound impacts on the stock prices of these biotechnology companies.


Download data is not yet available.

References or Bibliography

Abboud, L., & Kuchler, H. (2021, February 16). Why the three biggest vaccine makers failed on Covid-19. Retrieved from Financial Times:

Agrawal, G., Ahlawat, H., & Dewhurst, M. (2021, January 8). Biopharma 2020: A landmark year and a reset for the future. Retrieved from McKinsey & Company:

Aripaka, P., & Burger, L. (2021, June 12). EU adds another rare blood condition as side effect of AstraZeneca shot. Retrieved from Reuters:

Armstrong, D. (2020, December 23). The World’s Most Loathed Industry Gave Us a Vaccine in Record Time. Retrieved from Bloomberg Businessweek:

Baldo, V., Bertoncello, C., & Cocchio, S. (2016). The new pandemic influenza A/(H1N1)pdm09 virus: is it really "new"? The Journal of Preventive Medicine and Hygiene.

Barua, A. (2020, May 20). Economic impact of epidemics and pandemics in Asia since 2000. Retrieved from Deloitte Insights:

Bary, A. (2021, March 15). Big Pharma Battled the Pandemic. The Stocks Are Cheap. Retrieved from Barron's:

Barzani, E., & Maital, P. S. (2020). The Global Economic Impact of COVID-19: A Summary of Research. Retrieved from Samuel Neaman Institute for National Policy Research:

Bowler, J. (2021, April 21). Who’s making money from Covid-19 vaccines? Retrieved from Schroders:

Burger, Ludwig. “CureVac Fails in Pivotal COVID-19 Vaccine Trial with 47% EFFICACY.” Reuters, Thomson Reuters, 17 June 2021,

CDC. (n.d.). 2009 H1N1 Pandemic (H1N1pdm09 virus). Retrieved from Centers for Disease Control and Prevention:

CDC, NCIRD. (2019, May 8). 2009 H1N1 Pandemic Timeline. Retrieved from Centers for Disease Control and Prevention:

Cherry, J. D., & Krogstad, P. (2004). SARS: The First Pandemic of the 21st Century. Paediatric Research. Retrieved from Nature:

Chong, C. (2020, June 11). Coronavirus: Research that led to antiviral drug started in 2009. Retrieved from The Straits Times:

Cohen, J., & Kupferschmidt, K. (2020, October 28). The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug. Retrieved from Science:

Coniam, M. (2021, April 30). Stocks That Soared on Covid Treatments Are Coming Back to Earth By Morwenna Coniam 30 April 2021, 12:00 GMT+8 Vaccine rollout has undermined enthusiasm for drug development Some firms have abandoned efforts to create Covid treatments LISTEN TO ARTICLE 6. Retrieved from Bloomberg:

Corum, J., & Zimmer, C. (2021, May 7). How Moderna’s Vaccine Works. Retrieved from The New York Times:

Donald, H., & Yiping, H. (2004). The Impact of SARS on Asian Economies . Retrieved from Asian Economic Papers:

Drucker, J., & Gelles, D. (2020, July 25). Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine. Retrieved from The New York Times:

Ellyatt, H. (2021, April 27). Public demand for AstraZeneca vaccine falls in Britain after blood clot scares. Retrieved from CNBC:

Fontana, F. (2021, June 11). Moderna, GameStop, Stocks That Defined the Week. Retrieved from The Wall Street Journal:

Forum, W. E. (2020, February 19). 3 charts that compare coronavirus to previous outbreaks . Retrieved from World Economic Forum:

Gardner, J., Pagliarulo, N., & Fidler, B. (2021, June 1). Coronavirus vaccines are rolling out quickly. Here's where the pipeline stands. Retrieved from BIOPHARMADIVE:

Gatlin, A. (2021, August 6). Is Pfizer Stock A Buy As It Eyes $26 Billion In Full-Year Covid Vaccine Sales? Retrieved from Investor's Business Daily:

Gelles, D. (2020, October 15). U.S. Investigates Vaxart’s Claims Related to Covid-19 Vaccine. Retrieved from The New York Times:

Genexine, Inc. (2021). Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults.

Grandview Research. (2021). Biotechnology Market Size, Share & Trends Analysis Report By Technology (DNA Sequencing, Nanobiotechnology), By Application (Health, Bioinformatics), By Region, And Segment Forecasts, 2021 - 2028. Retrieved from

Gross, A., Peel, M., & Kuchler, H. (2021, May 29). Does the AstraZeneca vaccine have a future? Retrieved from Financial Times:

Hyun-tai, S. (2021, April 27). Genexine to supply Covid-19 vaccine candidate to Indonesia. Retrieved from Korea Biomedical Review:

Isaacs-Thomas, I. (2021, April 2). The powerful technology behind the Pfizer and Moderna vaccines. Retrieved from PBS News Hour:

Johnston, M. (2021, May 19). How Pfizer Makes Money. Retrieved from Investopedia:

Jr., B. L. (2020, April 17). Biotech stocks surge as people are ‘hungry’ for good news on the coronavirus. Retrieved from CNBC:

Kim, Y.-W., Yoon, S.-J., & Oh, I.-H. (2013). The economic burden of the 2009 pandemic H1N1 influenza in Korea. Scand J Infect Dis.

Kuchler, H., & Mooney, A. (2020, July 6). Pharma industry seizes on pandemic as a shot at redemption. Retrieved from Financial Times:

Langreth, R., Kresge, N., & Griffin, R. (2020, November 9). Pfizer Soars as Vaccine Prevents 90% of Covid Cases in Study. Retrieved from Bloomberg:

LeDuc, J. W., & Barry, A. M. (2004). SARS, the First Pandemic of the 21st Century. Emerging Infectious Diseases. Retrieved from ncbi:

Lee, A., & Cho, J. (2016). The impact of epidemics on labor market: identifying victims of the Middle East Respiratory Syndrome in the Korean labor market. International journal for equity in health. Retrieved from International Journal from Equity in Health:

Manufacturing Chemist. (2010, May 11). Pharma companies earned US$3.3bn on H1N1 vaccine. Retrieved from Manufacturing Chemist:

Morris, D. (2020, February 27). Coronavirus – Lessons from SARS for investors. Retrieved from Investors' Corner:

Padhy, I., Song, J., & Mahapatra, A. (2020, May) Role of Biotechnology in Pharmaceutical Research: A Comprehensive Review. Retrieved from ResearchGate:

Pardo, J., Shukla, A. M., Chamarthi, G., & Gupte, A. (2020). The journey of remdesivir: from Ebola to COVID-19. Drugs in Context.

Providence Therapeutics Holdings Inc. . (2021, February 21). PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64. Retrieved from

Reuters. (2021, June 1). India's Biological E. to make Providence Therapeutics' mRNA COVID-19 vaccine. Retrieved from Reuters:

Robbins, R., & Goodman, P. S. (2021, May 5). Pfizer Reaps Hundreds of Millions in Profits From Covid Vaccine. Retrieved from

Rojas, C. D. (2020, April 20). How Has Coronavirus Affected Europe’s Biotech Stocks? Retrieved from

Servick, K. (2020, March 25). This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines. Retrieved from Science:

Sharma, S., & Saiyed, T. (2021, April 23). Role of Biotechnology in India’s Fight Against the COVID-19 Pandemic. Retrieved from Carnegie India:

Smith, R. D., & Keogh-Brown, M. R. (2008). The economic impact of SARS: How does the reality match the predictions? Elsevier Public Health Emergency Collection. Retrieved from ncbi:

Smith, R. D., & Keogh‐Brown, M. R. (2013, July 4). Macroeconomic impact of a mild influenza pandemic and associated policies in Thailand, South Africa and Uganda: a computable general equilibrium analysis. Influenza Other Respir Viruses, 7(6). Retrieved from researchgate:

Steenhuysen, J. (2009, October 24). Companies reap the swine flu windfall. Retrieved from Reuters:

Steiner, R. (2021, March 11). AstraZeneca Shares Fall as Denmark Pauses Shots of Its Covid-19 Vaccine Following Blood Clots. Retrieved from Barron's:

Terry, M. (2021, May 26). UPDATED Comparing COVID-19 Vaccines: Timelines, Types and Prices. Retrieved from BioSpace:

Thompson, D. (2021, March 29). How mRNA Technology Could Change the World. Retrieved from The Atlantic:

Trefis Team. (2021, January 25). Should You Buy Johnson & Johnson Stock At $160? Retrieved from Forbes:

Trefis Team. (2021, March 1). Is Vaxart Stock Set To Decline Further? Retrieved from Forbes:

Trefis Team. (2021, April 29). Should You Buy Gilead Stock At $65? Retrieved from Forbes:

UW Applied Biotechnology,“What Is Biotechnology?” 21 Apr. 2021, Retrieved from

VAXART. (2020, October 14). Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine. Retrieved from VAXART:

Wee, S.-L., Corum, J., & Zimmer, C. (2021, June 10). Coronavirus Vaccine Tracker. Retrieved from The New York Times:

World Health Organisation. (2021). Influenza A (H1N1) outbreak. Retrieved from World Health Organisation:

World Health Organization. (2021). WHO Coronavirus (COVID-19) Dashboard. Retrieved from World Health Organisation:



How to Cite

Zhang, N., & Haskins, M. (2021). Trends of industry-leading biotechnology stocks during COVID-19. Journal of Student Research, 10(3).



HS Research Articles